HL Financial Services LLC lowered its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 90.9% during the second quarter, Holdings Channel reports. The institutional investor owned 4,715 shares of the biotechnology company’s stock after selling 47,278 shares during the period. HL Financial Services LLC’s holdings in Anika Therapeutics were worth $233,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC boosted its position in Anika Therapeutics by 110.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,335,175 shares of the biotechnology company’s stock worth $58,000,000 after buying an additional 700,234 shares in the last quarter. Thomson Horstmann & Bryant Inc. bought a new position in Anika Therapeutics during the second quarter worth $11,345,000. Columbia Wanger Asset Management LLC bought a new position in Anika Therapeutics during the first quarter worth $7,395,000. Wells Fargo & Company MN boosted its position in Anika Therapeutics by 891.4% in the first quarter. Wells Fargo & Company MN now owns 166,674 shares of the biotechnology company’s stock worth $7,240,000 after buying an additional 149,862 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in Anika Therapeutics by 935.0% in the first quarter. Stifel Financial Corp now owns 140,704 shares of the biotechnology company’s stock worth $6,119,000 after buying an additional 127,109 shares in the last quarter. Institutional investors own 82.25% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ ANIK) opened at 52.97 on Thursday. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $53.99. The firm has a market capitalization of $776.43 million, a PE ratio of 23.53 and a beta of 1.69. The firm’s 50-day moving average is $49.58 and its 200-day moving average is $47.07.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.44 by $0.32. The company had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The business’s revenue was up 25.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.57 EPS. On average, analysts anticipate that Anika Therapeutics Inc. will post $2.10 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Anika Therapeutics Inc. (ANIK) Shares Sold by HL Financial Services LLC” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/17/anika-therapeutics-inc-anik-shares-sold-by-hl-financial-services-llc.html.

A number of equities analysts have weighed in on ANIK shares. Zacks Investment Research upgraded shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 8th.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total transaction of $710,476.03. Following the sale, the chief executive officer now directly owns 246,740 shares in the company, valued at approximately $12,344,402.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffery S. Thompson sold 10,725 shares of the business’s stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $47.39, for a total transaction of $508,257.75. Following the sale, the director now owns 15,845 shares in the company, valued at $750,894.55. The disclosure for this sale can be found here. Insiders have sold a total of 88,725 shares of company stock worth $4,459,085 over the last 90 days. Insiders own 6.57% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.